Meet Aitia at the AD/PD Summit

AD/PD Summit

Join us at the AD/PD Summit in Lisbon, Portugal on March 5 – 9, 2024. This conference is exclusively focused on advancing innovative strategies in therapy, prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, and finally leading to the development of innovative therapies. Make sure […]

R&D Leadership Summit to Accelerate R&D Productivity Enhancement Opportunities

R&D Leadership Summit

The R&D Leadership Summit convenes industry experts and leaders from the biopharmaceutical field to delve into pivotal topics shaping the trajectory of research and development. On March 4th, our CEO, Colin Hill, will be part of a panel to discuss the transformative potential of AI and its profound implications in drug discovery. The discussion will center […]

Join Aitia at the GAP-Net Site Optimization Conference in New Orleans

GAP NET SITE OPTIMIZATION

Join Aitia at the GAP-Net Site Optimization Conference in New Orleans, Louisiana on Feb 28 – March 1, 2024. This conference is exclusively focused on enhancing clinical trials, bringing together clinical research leaders and executive teams from prominent Alzheimer’s and Parkinson’s disease clinical trial sites across North America, along with pharmaceutical sponsors, CROs, and other […]

Prediction of HD-related clinical outcome progression and imaging markers using AI-based Digital Twins to be Presented at HDTC 2024

CHDI HDTC

We are delighted to announce that Aitia will be at the upcoming 19th Annual Huntington’s Disease Therapeutics Conference being held from February 26-29 in Palm Springs, California. We will be presenting a poster focused on identification of gene pathways with direct causal relationships to Huntington’s Disease (HD) through Gemini Digital Twins of HD patients, based […]

Causal AI to learn “Gemini Digital Twins” for Drug Discovery and Clinical Development: Join our CMO, Bruce Church at AIRIS 2024

Airis 2024

We are excited to announce that Aitia will be participating at the AI Regulatory & International Symposium 2024 conference in Seoul, Korea. Our Chief Mathematics Officer, Bruce Church, will be taking the stage in the New Medical Products and Treatment Opportunities Using AI session to talk about Aitia’s commitment in accelerating AI-driven discoveries and share […]

Meet us at WSJ Health Forum

WSJ Health Forum

Join our CEO, Colin Hill with an influential community of scientists, business leaders, investors, policymakers and experts from across the sector to explore the trends, technologies, ideas and opportunities reshaping the business and science of health on Feb 21, 2024 in Boston at WSJ Forum. Find more details here.  

Unveiling the AI Dominance in Biopharma: STAT Post JPM Conference Insights

At health care’s biggest investor conference, AI’s high hopes collided with skepticism - STAT article

JPM conference has echoed discussions about AI across the biopharmaceutical landscape. Catch up on key insights shared in the latest STAT article titled: “At Health Care’s Biggest Investor Conference, AI’s High Hopes Collided with Skepticism.” Sanofi’s chief executive, Paul Hudson, revealed the widespread integration of AI within the company: “More than 11,000 people across the […]

Servier and Aitia Announce a New Collaboration Focused on Parkinson’s Disease

Aitia‘s Gemini Digital Twins will help identify subpopulations of patients who could respond favorably to Servier’s LRRK2 in development treatment Suresnes (France), 08 January 2024 – Servier, an independent international pharmaceutical group, and Aitia, the leader in the application of causal AI and Digital Twins, have strengthened today their partnership by signing a new contract […]

Servier Will Apply Aitia’s Gemini Digital Twins to Parkinson’s Drug

Servier Will Apply Aitia's Digital Twins to Parkinson’s Drug

Spotlight on our joint effort with Servier, strengthening our partnership by entering a new collaboration focused on neuroscience. The aim of this cooperation is to leverage Aitia’s Gemini Digital Twins to identify patients most likely to respond positively to Servier’s Leucine-Rich-Repeat-Kinase 2 inhibitor (LRRK2i) in development treatment for Parkinson’s disease. Read the full article on […]

Meet us at J.P.Morgan Healthcare Conference

J.P. Morgan

As we prepare to wrap up another exciting year for Aitia, we’re eagerly looking forward to a bustling 2024. For now, we’re gearing up for the J.P. Morgan conference, where our CEO, Colin Hill and President, COO, Jean-Michel Gries will be in attendance. Be sure to connect with them and request a meeting through the […]